Stu Dorman is dedicated to improving and extending the lives of people living with cancer and other serious diseases and has dedicated his professional career to delivering on this promise. Through collaborative leadership in the biotechnology, pharmaceutical, and healthcare consulting industries, he builds and energizes teams to overcome significant challenges and achieve impactful results for patients. 

Stu joined Gilead Sciences in 2020 as Vice President and U.S. Oncology Business Unit Head. In this role, Stu is building a new cancer franchise laser-focused on real leadership in the oncology space. His wealth of strategic and operational experience in oncology allows him to lead the organization on its path to deliver 20+ transformative indication approvals by 2030. 

Having joined Gilead from Bristol Myers Squibb, Stu there led the Worldwide Oncology Commercial business for the Opdivo, Yervoy and Abraxane franchises. Prior to that, as Head of Hematology Marketing, he was integral in the successful $74 billion commercial integration of Celgene in 2019. 

During more than 14 years at BMS, Stu held leadership positions across a wide range of functions including strategy, commercial operations, U.S. and global marketing, sales, and market access. Stu started his professional career in healthcare consulting at Trinity, where he led project teams to advance patient care. 

Stu holds a bachelor’s degree from Harvard University and an MBA from the Stanford University Graduate School of Business. In his free time, he is an avid cyclist, an outdoor enthusiast, and lives vicariously through the athletic endeavors of his two teenage children.